Butriptyline

Depression.

Adult: PO 25 mg 3 times/day. Max: 150 mg daily.

Recent MI, arrhythmias, severe liver disease, manic phase. Lactation.

CV disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, close-angle glaucoma, history of urinary retention, concurrent electroconvulsive therapy, diabetes. Pregnancy. Elderly and child. Porphyria. Avoid abrupt withdrawal. May cause drowsiness; do not drive or operate machinery.

Marked antimuscarinic effects, CV effects. Nausea, sweating, tremor, hypersensitivity reactions, behavioral disturbances, sexual dysfunction, blood sugar changes, increased appetite or wt gain. Testicular enlargement, gynecomastia, galactorrhea. Convulsion, movement disorders, dyskinesias. Fever and blood disorders.

Plasma conc and effects may be enhanced by concomitant use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir and verapamil. Side-effects may be increased by adrenaline, amiodarone, general anesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline,phenothiazine, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine and tramadol. Clonidine, barbiturates, nitrates and primidone are reduced while effects of baclofen, opioid analgesics and thyroid hormones are enhanced with concomitant use. Carbamazepine and rifampicin may increase metabolism while its effects may be antagonized by estrogens. Alcohol.

Antidepressants

N06AA15 - butriptyline ; Belongs to the class of non-selective monoamine reuptake inhibitors. Used in the management of depression.